In our previous study, orlistat could improve radiotherapy outcomes in both LNCaP cells and PC3 cells via inhibiting FASN activity and phosphorylation of AKT pathway in vitro and reduce the tumor volume in vivo [37]. Here, FASN is linked to neoplasm.